Mushrooms And Dmt: What's The Connection?

Psilocybin, also known as 4-phosphoryloxy-N,N-dimethyltryptamine (4-PO-DMT), is a naturally occurring psychedelic found in more than 200 species of mushrooms. It is closely related to the neurotransmitter serotonin and has hallucinogenic and serotonergic effects. Mushrooms containing psilocybin have been consumed for spiritual and divinatory purposes in Mesoamerica for thousands of years. Today, psilocybin is primarily sought after for its psychedelic effects, with users reporting euphoria, changes in perception, distorted sense of time, and spiritual experiences. Possession of psilocybin-containing mushrooms has been outlawed in most countries, and it is classified as a Schedule I controlled substance under the 1971 United Nations Convention on Psychotropic Substances. However, in recent years, there has been a reignited interest in the therapeutic potential of psychedelics, with well over 100 separate trials investigating their health applications.

Psilocybin-containing mushrooms are found in tropical and subtropical regions of South America, Mexico and the US

Psilocybin-containing mushrooms, commonly known as magic mushrooms or shrooms, are hallucinogenic mushrooms that contain the prodrug psilocybin, which turns into the psychedelic psilocin when ingested. The most potent species are members of the genus Psilocybe, such as P. azurescens, P. semilanceata, and P. cyanescens.

Psilocybin-containing mushrooms are found in tropical and subtropical regions of South America, Mexico, and the US. In the US, they grow most reliably in the damp, chill Pacific Northwest, where they can be found on excess carbon deposits like wood chips near urban spaces. The three most common Psilocybe varietals in the United States are P. cyanescens, P. allenii, and P. ovoideocystidiata. They are relatively small, averaging only 2-3 inches in height, and are often chestnut brown, turning a deep purplish-blue when crushed due to the presence of purple spores.

In Mexico and Central America, psilocybin mushrooms have been consumed in religious, divinatory, and spiritual contexts since prehistoric times. Spanish chroniclers first documented their use in the 16th century, and they were reportedly served at the coronation of the Aztec ruler Moctezuma II in 1502.

Psilocybe semilanceata, considered the world's most widely distributed psilocybin mushroom, is found in temperate parts of Europe, North America, Asia, South America, Australia, and New Zealand. Psilocybe cubensis, another common species, grows naturally in tropical and subtropical regions.

Psilocybin mushrooms have been consumed by humans for thousands of years, and their effects can include euphoria, changes in perception, a distorted sense of time, and spiritual experiences. However, they can also cause adverse reactions such as nausea and panic attacks, and higher doses are correlated with increased anxiety. Possession of psilocybin-containing mushrooms has been outlawed in most countries, and psilocybin is classified as a Schedule I controlled substance under the 1971 United Nations Convention on Psychotropic Substances.

Psilocybin is a naturally occurring psychedelic produced by over 200 species of mushrooms

Psilocybin, also known as 4-phosphoryloxy-N,N-dimethyltryptamine (4-PO-DMT), is a naturally occurring psychedelic produced by over 200 species of mushrooms, including Psilocybe cubensis, Psilocybe cyanescens, and Psilocybe mexicana. It is a prodrug of psilocin, which means that psilocybin itself is biologically inactive but is quickly converted by the body into psilocin. Psilocin is a serotonergic psychedelic that acts as a non-selective agonist of the serotonin receptors, producing effects such as euphoria, changes in perception, distorted sense of time, and spiritual experiences. It is also known to cause adverse reactions such as nausea and panic attacks.

The mushrooms containing psilocybin have been consumed for spiritual and divinatory purposes in Mesoamerica for centuries, with their use being documented by Spanish chroniclers in the 16th century. In 1958, Swiss chemist Albert Hofmann isolated psilocybin and psilocin from the Psilocybe mexicana mushroom, and his employer, Sandoz, marketed and sold pure psilocybin for psychedelic therapy. However, the increasing drug restrictions in the 1960s and 1970s hindered scientific research on psilocybin and other hallucinogens. Despite this, the popularity of psilocybin mushrooms grew due to the increased availability of information on their cultivation.

Psilocybin-containing mushrooms vary in their psilocybin and psilocin content, typically ranging around 1% of the dried weight of the mushrooms. The effects of psilocybin can be subjectively perceived at doses as low as 3 mg per 70 kg body weight, with intermediate or "good effect" doses being around 20 mg, and high or ego-dissolution doses ranging from 30 to 40 mg. Microdosing of psilocybin involves the use of subthreshold doses of less than 2.5 mg.

Psilocybin is part of a family of molecules called indolamines, which also includes DMT, LSD, and serotonin. The psychedelic effects of psilocybin are believed to be exerted through the activation of the 5-HT2A receptor, similar to DMT. However, compared to psilocybin, DMT is rapidly metabolized in the body, and research on DMT is less advanced.

While possession of psilocybin-containing mushrooms has been outlawed in most countries, there has been a recent wave of clinical research investigating the therapeutic potential of psychedelics, including psilocybin. This interest has been sparked by landmark studies demonstrating the effectiveness of these compounds in treating mood disorders. As a result, psilocybin has been decriminalized in several US cities, and its health applications are being explored in over 100 separate trials.

Psilocybin mushrooms have been used for spiritual and divinatory purposes for thousands of years

Psilocybin mushrooms, also known as magic mushrooms, have a long history of use for spiritual and divinatory purposes. In Mesoamerica, indigenous peoples have consumed psilocybin mushrooms in spiritual and divinatory ceremonies for thousands of years, with the first recorded instances by Spanish chroniclers in the 16th century.

Psilocybin is a naturally occurring psychedelic produced by over 200 species of mushrooms, including Psilocybe cubensis, Psilocybe cyanescens, and Psilocybe mexicana. These mushrooms typically contain around 1% of psilocybin and psilocin by dried weight, with psilocin being about 1.4 times as potent as psilocybin.

Psilocybin mushrooms have been used for their hallucinogenic and serotonergic effects, which can induce euphoria, changes in perception, a distorted sense of time, and spiritual experiences. The active compounds psilocybin and psilocin act on serotonin receptors in the brain, specifically the 5-HT2A receptor, to produce their psychoactive effects.

In the late 1950s, Swiss chemist Albert Hofmann isolated psilocybin and psilocin from the mushroom Psilocybe mexicana. This led to the marketing and sale of pure psilocybin to physicians and clinicians worldwide for use in psychedelic therapy. However, the increasing drug restrictions of the 1960s and 1970s curbed scientific research into psilocybin and other hallucinogens.

Despite the restrictions, interest in the therapeutic potential of psilocybin mushrooms has persisted, and in recent years, there has been a resurgence in clinical research into their potential benefits for treating mood disorders and other mental health applications. Today, psilocybin-containing mushrooms are illegal in most countries, but some jurisdictions have decriminalized their use, recognizing their traditional and potential therapeutic value.

Psilocybin is a prodrug of psilocin, which is the pharmacologically active agent in the body after ingestion

Psilocybin, also known as 4-phosphoryloxy-N,N-dimethyltryptamine (4-PO-DMT), is a naturally occurring tryptamine alkaloid and investigational drug, found in more than 200 species of mushrooms, including Psilocybe cubensis, Psilocybe cyanescens, and Psilocybe mexicana. Psilocybin is a prodrug of psilocin, which means that the compound itself is biologically inactive but is quickly converted by the body into psilocin, the pharmacologically active agent. Psilocybin is transformed into psilocin by dephosphorylation mediated via phosphatase enzymes.

Psilocybin has hallucinogenic and serotonergic effects, including euphoria, changes in perception, a distorted sense of time (via brain desynchronization), and perceived spiritual experiences. It can also cause adverse reactions such as nausea and panic attacks. The effects of psilocybin depend on set and setting and one's expectations. Its effects are mediated by its affinity for a range of serotonin receptors, particularly the 5-HT2A receptor, a serotonin receptor that is widely distributed in the central nervous system.

Psilocybin-containing mushrooms vary in their psilocybin and psilocin content but typically contain around 1% of the dried weight of the mushrooms in terms of their total or combined content. Psilocin is about 1.4 times as potent as psilocybin due to their difference in molecular weight. Low doses of psilocybin are 5 to 10 mg, an intermediate or "good effect" dose is 20 mg, and high or ego-dissolution doses are 30 to 40 mg. Microdosing involves the use of subthreshold psilocybin doses of less than 2.5 mg.

Psilocybin was first isolated and named in 1958 by Swiss chemist Albert Hofmann, who obtained the chemical from laboratory-grown specimens of the entheogenic mushroom Psilocybe mexicana. Hofmann's employer, Sandoz, marketed and sold pure psilocybin to physicians and clinicians worldwide for use in psychedelic therapy. However, the increasing restrictiveness of drug laws in the 1960s and 1970s curbed scientific research into the effects of psilocybin and other hallucinogens. Possession of psilocybin-containing mushrooms has been outlawed in most countries, and psilocybin has been classified as a Schedule I controlled substance under the 1971 United Nations Convention on Psychotropic Substances.

In recent years, there has been a reignited interest in the therapeutic potential of psychedelics, with landmark studies showing their effectiveness in treating mood disorders. This has kickstarted a wave of clinical research, with over 100 separate trials now investigating the health applications of psychedelics.

Psilocybin is illegal in most countries, but has been decriminalised in several US cities

Psilocybin, also known as 4-phosphoryloxy-N,N-dimethyltryptamine (4-PO-DMT), is a naturally occurring tryptamine alkaloid found in more than 200 species of mushrooms. It is often referred to as "magic mushrooms" or "shrooms" and has been consumed by humans for centuries for spiritual and healing purposes. Despite its long history of use, psilocybin is currently illegal in most countries and is classified as a Schedule I controlled substance under the 1971 United Nations Convention on Psychotropic Substances. This means that it is considered to have a high potential for abuse and no accepted medical use.

However, there has been a growing movement to decriminalize and legalize psilocybin in recent years, particularly in the United States. As of 2024, several US cities and states have taken steps to decriminalize or legalize psilocybin, including Oregon, Colorado, Washington, D.C., Michigan, Massachusetts, and California. In these jurisdictions, arrests for possession or use of psilocybin are often the lowest priority for law enforcement, or the substance is legal for specific medical or therapeutic purposes. For example, in Oregon, psilocybin has been legalized for mental health treatment in supervised settings since November 2020.

The push for decriminalization in the US is driven by several factors. Firstly, advocates cite research suggesting that psilocybin is non-addictive and causes fewer emergency visits compared to other illegal drugs. Secondly, there is growing recognition of the therapeutic and medicinal potential of psilocybin, particularly in treating treatment-resistant depression and nicotine dependence. Additionally, decriminalization advocates argue that law enforcement resources could be better utilized if redirected from policing private psychedelic usage. Finally, the rapid legalization of cannabis in the US has also influenced the movement to decriminalize psilocybin.

While psilocybin remains illegal in most countries, there are some exceptions and movements towards decriminalization or legalization in other parts of the world. For example, psilocybin is legal to possess and use in the British Virgin Islands, Jamaica, and Nepal. In Switzerland, psychedelic therapy has been legal since 2014, but only on official request. Other countries, such as Portugal, Spain, and the Czech Republic, have decriminalized personal possession and use of all drugs or specific substances, including psilocybin. These changing legal landscapes are often driven by increasing scientific research and political support for the therapeutic benefits of psychedelics.

Frequently asked questions